Our animal model and clinical data also suggest that the lack of an observed ACE inhibition protective effect could be because the drug was started well after KTx due to concerns of hyperkalemia, reduced renal perfusion, hypotension, and anemia (84). The gene discussed is ACE; the disease is anemia (phenotype).